S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ASND Ascendis Pharma AS

124.45

0.01 (0.01%)

Last Updated: 10:20:10

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Ascendis Pharma AS Charts.

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Ascendis Pharma AS Charts.

Ascendis Pharma AS News

Form 144 - Report of proposed sale of securities
Tuesday 19 November 2024 (19 hours ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (6 days ago) • Edgar (US Regulatory)

Ascendis Pharma Reports Third Quarter 2024 Financial Results
Thursday 14 November 2024 (6 days ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (6 days ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (6 days ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 13 November 2024 (7 days ago) • Edgar (US Regulatory)

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Thursday 7 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 4 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
Monday 4 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 9 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 30 September 2024 (2 months ago) • Edgar (US Regulatory)

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
Monday 30 September 2024 (2 months ago) • GlobeNewswire Inc.

More Ascendis Pharma AS News Articles

Sincerity Applied Materi... (PK)

TPT Global Tech (PK)

Intergrated Cannabis Sol... (PK)

Federal Home Loan Mortgage (QB)

Voip Pal Com (QB)

Apple Rush (PK)

Moon Equity (PK)

Net Savings Link (PK)

AMC Entertainment

Liquidmetal Technologies (QB)

Asia Broadband (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions